{
  "company": {
    "name": "Axcynsis Therapeutics",
    "website": "https://axcynsis.com/",
    "record": "https://startuphistory.org/c/axcynsis.com"
  },
  "status": null,
  "history_since": "2022-10-02T16:28:58.000Z",
  "baseline": {
    "snapshot_id": "c72239a8dcf4b73fb5218ca9a6137035e34083703546c84d8d962f4587c02b68",
    "observed_at": "2022-10-02T16:28:58.000Z",
    "headline": "Synthesizing the X-factor",
    "description": "About Us Axcynsis Therapeutics is a platform-based biotechnology company focusing on the development of Antibody-X Conjugate (AXC) therapies to revolutionise cancer treatments. Leveraging on proprieta",
    "evidence": "https://web.archive.org/web/20221002162858/https://axcynsis.com/",
    "evidence_kind": "internet_archive",
    "facts": null,
    "basis": "first_observation",
    "is_change": false
  },
  "live_captures": 1,
  "last_checked": "2026-11-05T11:45:16.129Z",
  "live_status": null,
  "messaging": [
    {
      "quote_observed_at": "2023-02-16T03:48:07.000Z",
      "variants": [
        {
          "headline": "Synthesizing the X-factor",
          "subhead": "About Us Axcynsis Therapeutics is a platform-based biotechnology company focusing on the development of Antibody-X Conjugate (AXC) therapies to revolutionise cancer treatments. Leveraging on proprieta",
          "observed_at": "2022-10-02T16:28:58.000Z",
          "evidence": "https://web.archive.org/web/20221002162858/https://axcynsis.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Synthesizing the X-factor",
          "subhead": "About Us Axcynsis Therapeutics is a platform-based biotechnology company focusing on the development of Antibody-X Conjugate (AXC) therapies to revolutionise cancer treatments. Leveraging on proprieta",
          "observed_at": "2023-02-16T03:48:07.000Z",
          "evidence": "https://web.archive.org/web/20230216034807/https://axcynsis.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "Synthesizing the X-factor",
      "subhead": "About Us Axcynsis Therapeutics is a platform-based biotechnology company focusing on the development of Antibody-X Conjugate (AXC) therapies to revolutionise cancer treatments. Leveraging on proprieta",
      "from": "2022-10-02T16:28:58.000Z",
      "to": "2023-02-16T03:48:07.000Z",
      "captures": 2,
      "evidence": "https://web.archive.org/web/20230216034807/https://axcynsis.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "between": {
          "from": "2022-10-02T16:28:58.000Z",
          "to": "2023-02-16T03:48:07.000Z"
        }
      },
      "current": false
    },
    {
      "quote_observed_at": "2026-11-05T11:45:16.129Z",
      "variants": [
        {
          "headline": "A ntibody- X C onjugate S yn the sis",
          "subhead": "About Us Axcynsis Therapeutics is a platform-based biotechnology company focusing on the development of Antibody-X Conjugate (AXC) therapies to revolutionise cancer treatments. Leveraging on proprieta",
          "observed_at": "2023-08-20T15:22:29.000Z",
          "evidence": "https://web.archive.org/web/20230820152229/https://axcynsis.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "A ntibody- X C onjugate S yn the sis",
          "subhead": "About Us Axcynsis Therapeutics is a platform-based biotechnology company focusing on the development of Antibody-X Conjugate (AXC) therapies to revolutionise cancer treatments. Leveraging on proprieta",
          "observed_at": "2024-02-26T12:26:01.000Z",
          "evidence": "https://web.archive.org/web/20240226122601/https://axcynsis.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "A ntibody- X C onjugate S yn the sis",
          "subhead": "About Us Axcynsis Therapeutics is a platform-based biotechnology company focusing on the development of Antibody-X Conjugate (AXC) therapies to revolutionise cancer treatments. Leveraging on proprieta",
          "observed_at": "2024-08-04T15:28:40.000Z",
          "evidence": "https://web.archive.org/web/20240804152840/https://axcynsis.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "A ntibody- X C onjugate S yn the sis",
          "subhead": "About Us Axcynsis Therapeutics is a platform-based biotechnology company focusing on the development of Antibody-X Conjugate (AXC) therapies to revolutionise cancer treatments. Leveraging on proprieta",
          "observed_at": "2025-02-14T21:46:52.000Z",
          "evidence": "https://web.archive.org/web/20250214214652/https://axcynsis.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "A ntibody- X C onjugate S yn the sis",
          "subhead": "About Us Axcynsis Therapeutics is a platform-based biotechnology company focusing on the development of Antibody-X Conjugate (AXC) therapies to revolutionise cancer treatments. Leveraging on proprieta",
          "observed_at": "2025-07-18T01:38:33.000Z",
          "evidence": "https://web.archive.org/web/20250718013833/https://axcynsis.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "A ntibody- X C onjugate S yn the sis",
          "subhead": "About Us Axcynsis Therapeutics is a platform-based biotechnology company focusing on the development of Antibody-X Conjugate (AXC) therapies to revolutionise cancer treatments. Leveraging on proprieta",
          "observed_at": "2026-02-18T12:45:02.000Z",
          "evidence": "https://web.archive.org/web/20260218124502/https://axcynsis.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "A ntibody- X C onjugate S yn the sis",
          "subhead": "About Us Axcynsis Therapeutics is a platform-based biotechnology company focusing on the development of Antibody-X Conjugate (AXC) therapies to revolutionise cancer treatments. Leveraging on proprieta",
          "observed_at": "2026-07-11T05:56:40.000Z",
          "evidence": "https://web.archive.org/web/20260711055640/https://axcynsis.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "A ntibody- X C onjugate S yn the sis",
          "subhead": "About Us Axcynsis Therapeutics is a platform-based biotechnology company focusing on the development of Antibody-X Conjugate (AXC) therapies to revolutionise cancer treatments. Leveraging on proprieta",
          "observed_at": "2026-11-05T11:45:16.129Z",
          "evidence": "https://axcynsis.com/",
          "evidence_kind": "live_capture"
        }
      ],
      "headline": "A ntibody- X C onjugate S yn the sis",
      "subhead": "About Us Axcynsis Therapeutics is a platform-based biotechnology company focusing on the development of Antibody-X Conjugate (AXC) therapies to revolutionise cancer treatments. Leveraging on proprieta",
      "from": "2023-08-20T15:22:29.000Z",
      "to": "2026-11-05T11:45:16.129Z",
      "captures": 8,
      "evidence": "https://axcynsis.com/",
      "evidence_kind": "live_capture",
      "seen": {
        "between": {
          "from": "2023-08-20T15:22:29.000Z",
          "to": "2026-11-05T11:45:16.129Z"
        }
      },
      "current": true
    }
  ],
  "changes": [
    {
      "n": 1,
      "id": "page-0db4b1c6413a1d0fb76771ab59fda729134ca49983ad10eb5e9c2db287368a41:d0a533f60fca3677ad8c2c30f2f91d5284425939c74ec3d5c2540fec2f63b18e:headline:577ceda47093ba01",
      "before_evidence": "https://web.archive.org/web/20230216034807/https://axcynsis.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "headline",
      "label": "Headline",
      "summary": "Changed its homepage headline from “Synthesizing the X-factor” to “A ntibody- X C onjugate S yn the sis”.",
      "between": {
        "from": "2023-02-16T03:48:07.000Z",
        "to": "2023-08-20T15:22:29.000Z"
      },
      "evidence": "https://web.archive.org/web/20230820152229/https://axcynsis.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": null
    }
  ],
  "update": null,
  "method": {
    "version": "messaging-v1",
    "description": "https://startuphistory.org/method"
  },
  "license": "CC-BY-4.0",
  "cite": "StartupHistory, “Axcynsis Therapeutics” company record, https://startuphistory.org/c/axcynsis.com"
}